ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics ...

Silo Pharma, Inc. announced a service agreement with Resyca BV to conduct a drug-device study on its microchip-based nasal spray system for SPC-15, an intranasal treatment for PTSD. This study aims to ...

SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...

Concurrently, a device study of the formulation-specific microchip-based nasal spray system used in SPC-15 is being conducted. Early data on SPC-15 indicated that its optimized patient safety profile ...

Investigational New Drug (IND) submission to FDA on target forQ1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS ...

A new economic impact study says South Plains College produces significant returns for the area's economy, students, businesses and taxpayers. The study reached three major conclusions. South Plains ...

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...

Thursday, Silo Pharma Inc (NASDAQ:SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The ...

SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug ...

Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma (SILO), Inc. (“the Company”), a ...